8 de marzo de 2017 / 14:52 / hace 5 meses

BRIEF-Intersect ENT submits new drug application to FDA for office-based resolve steroid releasing implant for recurrent chronic sinus disease

March 8 (Reuters) - Intersect ENT Inc

* Intersect ENT submits new drug application to FDA for office-based resolve steroid releasing implant for recurrent chronic sinus disease

* Intersect ENT - Trial met both co-primary efficacy endpoints, demonstrating a statistically significant reduction in nasal congestion and polyp burden

* Intersect ENT Inc - Submission supported by four clinical studies evaluating safety and effectiveness Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below